Shares of IRIDEX Co. (NASDAQ:IRIX) crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.94 and traded as high as $2.00. IRIDEX shares last traded at $1.91, with a volume of 3,089 shares trading hands.
Several brokerages recently commented on IRIX. ValuEngine downgraded shares of IRIDEX from a “buy” rating to a “hold” rating in a research report on Tuesday, September 22nd. Zacks Investment Research downgraded shares of IRIDEX from a “buy” rating to a “hold” rating in a research report on Tuesday, June 23rd.
The company has a current ratio of 3.40, a quick ratio of 2.37 and a debt-to-equity ratio of 0.13. The firm has a market cap of $26.52 million, a PE ratio of -3.41 and a beta of 1.12. The company’s 50-day moving average is $2.02 and its 200 day moving average is $1.94.
IRIDEX (NASDAQ:IRIX) last issued its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported ($0.20) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.03. The business had revenue of $6.22 million during the quarter, compared to the consensus estimate of $5.04 million. IRIDEX had a negative net margin of 20.65% and a negative return on equity of 35.91%. On average, research analysts predict that IRIDEX Co. will post -0.61 EPS for the current fiscal year.
IRIDEX Company Profile (NASDAQ:IRIX)
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.
Recommended Story: Why Net Income is Important to Investors
Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.